MX366570B - Formulaciones de 5-fluorocitosina y usos de las mismas. - Google Patents
Formulaciones de 5-fluorocitosina y usos de las mismas.Info
- Publication number
- MX366570B MX366570B MX2016002131A MX2016002131A MX366570B MX 366570 B MX366570 B MX 366570B MX 2016002131 A MX2016002131 A MX 2016002131A MX 2016002131 A MX2016002131 A MX 2016002131A MX 366570 B MX366570 B MX 366570B
- Authority
- MX
- Mexico
- Prior art keywords
- luorocytosine
- treating
- cancer
- subject
- another aspect
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 title 1
- 229960004413 flucytosine Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 102000000311 Cytosine Deaminase Human genes 0.000 abstract 1
- 108010080611 Cytosine Deaminase Proteins 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04001—Cytosine deaminase (3.5.4.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La descripción proporciona una formulación de liberación prolongada de 5-fluorocitosina. En otro aspecto, se proporciona un método para tratar una enfermedad fungal. El método comprende administrar a un sujeto en necesidad del mismo una cantidad efectiva tratadora del hongo de una composición que comprende 5-fluorocitosina. En todavía otro aspecto, se proporciona un método para tratar un cáncer. El método comprende administrar a un sujeto en necesidad del mismo una cantidad suficiente de un vector de expresión para inducir la expresión de citosina desaminasa que es capaz de convertir 5-fluorocitosina a 5-fluoruracilo en células del cáncer y una cantidad efectiva tratadora del cáncer de una composición que comprende 5-fluorocitosina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7714208P | 2008-06-30 | 2008-06-30 | |
| PCT/US2009/049322 WO2010002937A1 (en) | 2008-06-30 | 2009-06-30 | Formulations of 5-fluorocytosine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX366570B true MX366570B (es) | 2019-07-12 |
Family
ID=41466310
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002131A MX366570B (es) | 2008-06-30 | 2009-06-30 | Formulaciones de 5-fluorocitosina y usos de las mismas. |
| MX2010014256A MX337213B (es) | 2008-06-30 | 2009-06-30 | Formulaciones de 5-fluorocitosina y usos de las mismas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010014256A MX337213B (es) | 2008-06-30 | 2009-06-30 | Formulaciones de 5-fluorocitosina y usos de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9320738B2 (es) |
| EP (1) | EP2306823A4 (es) |
| JP (3) | JP6092514B2 (es) |
| KR (2) | KR101950635B1 (es) |
| CN (2) | CN107029220A (es) |
| AU (1) | AU2009267052B2 (es) |
| BR (1) | BRPI0915284B1 (es) |
| CA (1) | CA2724740C (es) |
| IL (3) | IL209385A (es) |
| MX (2) | MX366570B (es) |
| WO (1) | WO2010002937A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1115290T3 (da) | 1998-10-01 | 2009-06-22 | Univ Southern California | Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf |
| AU2009267052B2 (en) * | 2008-06-30 | 2013-07-11 | Tocagen Inc. | Formulations of 5-fluorocytosine and uses thereof |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| EP2346995B1 (en) * | 2008-09-26 | 2018-11-07 | Tocagen Inc. | Gene therapy vectors and cytosine deaminases |
| JP5923037B2 (ja) | 2009-06-17 | 2016-05-24 | トカジェン インコーポレーテッド | 複製可能レトロウイルスベクターの産生細胞 |
| WO2011057176A1 (en) * | 2009-11-06 | 2011-05-12 | Forest Laboratories Holding Limited | Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
| WO2012058673A2 (en) | 2010-10-31 | 2012-05-03 | Tocagen Inc. | Enhanced cancer treatment and monitoring using recombinant vectors |
| US10130684B2 (en) * | 2011-02-03 | 2018-11-20 | Pharmedica Ltd. | Oral dissolving films for insulin administration, for treating diabetes |
| WO2013004658A1 (en) * | 2011-07-01 | 2013-01-10 | Transgene Sa | Formulations of 5-fluorocytosine and uses thereof. |
| CN102579450B (zh) * | 2012-02-10 | 2013-07-24 | 上海市嘉定区南翔医院 | 5-氟尿嘧啶在制备局限性慢性湿疹治疗药物上的应用 |
| EP2668945A1 (de) | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
| US11065311B2 (en) | 2012-10-25 | 2021-07-20 | Denovo Biopharma Llc | Retroviral vector with mini-promoter cassette |
| US9642921B2 (en) | 2012-12-20 | 2017-05-09 | Tocagen Inc. | Cancer combination therapy and recombinant vectors |
| MX2018002744A (es) | 2015-09-04 | 2018-04-13 | Tocagen Inc | Vectores recombinantes que comprenden peptido 2a. |
| EP3595675A4 (en) * | 2017-03-14 | 2020-12-30 | Memorial Sloan Kettering Cancer Center | MARKING, ISOLATION AND ANALYSIS OF RNA FROM RARE CELLULAR POPULATIONS |
| US20190380965A1 (en) * | 2018-06-15 | 2019-12-19 | Hemant N. Joshi | Quick Water-Dispersible Pharmaceutical Compositions of Flucytosine |
| EP3955943A4 (en) * | 2019-02-22 | 2023-10-25 | Candel Therapeutics, Inc. | Gmci and ddri combination therapy for treating cancer |
| WO2021186399A1 (en) | 2020-03-18 | 2021-09-23 | Marvell Israel (M.I.S.L) Ltd. | Packet buffer spill-over in network devices |
| CN111937887B (zh) * | 2020-07-15 | 2021-09-07 | 南京师范大学 | 5-氟-2’-脱氧尿苷在抑制和/或防治螺旋藻规模化生产中褶皱臂尾轮虫的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL101144A (en) | 1991-03-06 | 1996-09-12 | Wellcome Found | Pharmaceutical compositions containing 1-(2-hydroxymethyl)-1,3-oxathiolan-5-fluorocytosine and derivatives thereof for the treatment of hepatitis b virus infections |
| FI980901A (fi) | 1998-04-23 | 1999-10-24 | Orion Yhtymae Oyj | Levosimendaania säädellysti vapauttavia oraalisia koostumuksia |
| DK1115290T3 (da) | 1998-10-01 | 2009-06-22 | Univ Southern California | Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf |
| EA200401009A1 (ru) * | 1999-03-31 | 2004-12-30 | Янссен Фармацевтика Н.В. | Предварительно желатинированный крахмал в композиции с контролируемым высвобождением |
| US6677155B1 (en) | 1999-04-22 | 2004-01-13 | The General Hospital Corporation | Triple hybrid amplicon vector systems to generate retroviral packaging lines |
| WO2001004266A1 (en) | 1999-07-08 | 2001-01-18 | The Regents Of The Universty Of California | A lung cancer associated retrovirus, gene delivery vector and methods of use thereof |
| JP4021627B2 (ja) * | 2000-03-22 | 2007-12-12 | 株式会社東芝 | 遺伝子検出用担体、及びインターフェロン療法の有効性を検出するためのその使用 |
| KR20030013460A (ko) | 2000-06-23 | 2003-02-14 | 테바 파마슈티컬 인더스트리즈 리미티드 | 치료제의 위 체류 및 방출 조절을 위한 급속 팽창성조성물과 이 조성물을 포함하는 제형 |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US7186699B2 (en) * | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| CN1244321C (zh) * | 2003-06-26 | 2006-03-08 | 李勇 | 用于胃癌治疗的5－氟尿嘧啶胃内漂浮滞留双层缓释片 |
| US20050049207A1 (en) | 2003-09-03 | 2005-03-03 | Kaufmann Doug A. | Method of treating and preventing cancer |
| WO2006014427A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
| FR2874325B1 (fr) | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
| WO2006127980A2 (en) | 2005-05-25 | 2006-11-30 | The Regents Of The University Of California | Optimized core promoters and uses therefor |
| WO2007069358A1 (ja) * | 2005-12-14 | 2007-06-21 | Kissei Pharmaceutical Co., Ltd. | 新規胃内滞留製剤 |
| CN101085355B (zh) * | 2007-06-20 | 2012-01-25 | 山东大学 | 5-氟胞嘧啶/类水滑石纳米杂化物及其制备方法 |
| US20090068287A1 (en) | 2007-09-12 | 2009-03-12 | Susan Welsh | Novel topical formulations of flucytosine and uses thereof |
| US9314524B2 (en) | 2007-12-31 | 2016-04-19 | Calla Therapeutics Llc | Topical formulations of Flucytosine |
| AU2009267052B2 (en) * | 2008-06-30 | 2013-07-11 | Tocagen Inc. | Formulations of 5-fluorocytosine and uses thereof |
| EP2346995B1 (en) | 2008-09-26 | 2018-11-07 | Tocagen Inc. | Gene therapy vectors and cytosine deaminases |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| US9187762B2 (en) | 2010-08-13 | 2015-11-17 | Pioneer Hi-Bred International, Inc. | Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (HPPD) activity |
-
2009
- 2009-06-30 AU AU2009267052A patent/AU2009267052B2/en not_active Ceased
- 2009-06-30 CN CN201710036517.XA patent/CN107029220A/zh active Pending
- 2009-06-30 EP EP09774387A patent/EP2306823A4/en not_active Withdrawn
- 2009-06-30 KR KR1020177036825A patent/KR101950635B1/ko active IP Right Grant
- 2009-06-30 MX MX2016002131A patent/MX366570B/es unknown
- 2009-06-30 JP JP2011516833A patent/JP6092514B2/ja active Active
- 2009-06-30 US US13/001,516 patent/US9320738B2/en active Active
- 2009-06-30 WO PCT/US2009/049322 patent/WO2010002937A1/en active Application Filing
- 2009-06-30 KR KR1020117002457A patent/KR101813721B1/ko active IP Right Grant
- 2009-06-30 MX MX2010014256A patent/MX337213B/es active IP Right Grant
- 2009-06-30 CA CA2724740A patent/CA2724740C/en not_active Expired - Fee Related
- 2009-06-30 BR BRPI0915284A patent/BRPI0915284B1/pt not_active IP Right Cessation
- 2009-06-30 CN CN200980125558XA patent/CN102076215A/zh active Pending
-
2010
- 2010-11-17 IL IL209385A patent/IL209385A/en active IP Right Grant
-
2014
- 2014-11-07 JP JP2014227208A patent/JP6170896B2/ja active Active
-
2016
- 2016-04-22 US US15/136,056 patent/US9889133B2/en active Active
- 2016-06-27 IL IL246473A patent/IL246473B/en active IP Right Grant
-
2017
- 2017-07-03 JP JP2017130096A patent/JP2017214398A/ja active Pending
- 2017-11-21 IL IL255813A patent/IL255813A/en unknown
-
2018
- 2018-02-07 US US15/891,243 patent/US10449194B2/en active Active
-
2019
- 2019-10-16 US US16/654,318 patent/US11191764B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX337213B (es) | Formulaciones de 5-fluorocitosina y usos de las mismas. | |
| BR112015007878A2 (pt) | composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos | |
| NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
| GB2472964A (en) | Vectors for delivery of light-sensitive proteins and methods of use | |
| LT2999791T (lt) | Modifikuotos kapsidės, raav3 vektoriaus kompozicijos ir panaudojimo būdai žmogaus kepenų vėžio genų terapijoje | |
| MX369616B (es) | Composiciones cutaneas y metodos para su uso. | |
| PH12013500441A1 (en) | Materials and methods for improving gastrointestinal function | |
| BR112012021296A2 (pt) | imunoconjugados e anticorpos de receptor de folato 1 e usos dos mesmos. | |
| BR112013010853A2 (pt) | "agentes citotóxicos compreendendo derivados de ansamitocina, composição farmacêutica e uso destes" | |
| EP2244714A4 (en) | USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER | |
| TN2012000161A1 (en) | Spiro-oxindole mdm2 antagonists | |
| MX341119B (es) | Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail). | |
| DK2252322T3 (da) | Vaccinesammensætninger | |
| BRPI0912292A2 (pt) | composições e métodos para o uso de células no tratamento do tecido cardíaco. | |
| PH12014501639A1 (en) | Pharmaceutical compositions and methods | |
| MX2012010434A (es) | Compuestos y composiciones novedosas para atacar a las celulas madre del cancer. | |
| WO2009114703A3 (en) | Combination therapy for the treatment of cancer | |
| MX2011011596A (es) | Perifosina y capecitabina como un tratamiento combinado para cancer. | |
| BRPI0810384B8 (pt) | terapia enzimática anticâncer | |
| EP2249826A4 (en) | COMPOSITIONS AND METHODS OF USING COMPOUNDS TO EXTEND THE SURVIVAL PERIOD OF CANCER PATIENTS | |
| WO2011130697A3 (en) | Tissue targeting | |
| MX338100B (es) | Celulas derivadas de tejido cardiaco. | |
| ES2479540T3 (es) | Células, construcciones de ácidos nucleicos, células que comprenden dichas construcciones y métodos de utilización de dichas células en el tratamiento de enfermedades | |
| RS54442B1 (en) | USE OF S-ADENOSYLMETHIONINE (SAM) AND SUPEROXIDE DISMUTASE (SOD) FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF ALCHAIMER DISEASE | |
| ITBO20080297A1 (it) | Composizione enzimatica per ridurre il rilascio di principi attivi farmaceutici nell'ambiente. |